Jorge García-González

Oncoloxía Médica - Hospital Clínico Universitario de Santiago

ONCOMET – Instituto de Investigación Sanitaria de Santiago

CIBERONC, Madrid

• Honorarios por Advisory boards: Lilly; Astra Zeneca; BoehringerIngelheim; Hoffmann-La Roche; Bristol-Myers-Squib; Merck Sharp & Dohme; Pierre-Fabre

• Cursos de formación continuada ou congresos (inclúe inscripción, gastos de desprazamento e aloxamento): Lilly; Astra Zeneca; Hoffmann-La Roche; Bristol-Myers-Squib; Merck Sharp & Dohme; Pfizer; Ipsen

http://www.grupogallegocancerdepulmon.org

1. Desenrolar, estimular e coordinar estudos en todos os aspectos relativos ao cancro de pulmón

2. Organizar congresos, simposios e conferencias para promover ditosestudos

3. Desenrolar futuras investigacións noutras patoloxías

http://www.grupogallegocancerdepulmon.org

0

1

2

3

4

5

20122013

20142015

20162017

20182019

Número de comunicaciones

2012 2013 2014 2015 2016 2017 2018 2019

Inmunoterapia; 3

Quimiorradioterapia; 2

Poblacións especiais; 2

Terapias dirixidas; 5

Biomarcadores; 1

PUBLICACIÓNS EN ASCO

ANO TÍTULO DA PUBLICACIÓN

2012 GGCP041/09: A Galician study of second-line erlotinib in patients with advanced non-squamous non-small cell lung cancer (nsNSCLC)1

Erlotinib as frontline treatment for elderly patients (p) with advanced non-squamous non-small cell lung cancer (nsNSCLC): GGCP044/09 study2

2019

Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation3

Galician lung cancer group: Afatinib´s data as first-line treatment for elderly patients4

Efficacy and safety of Crizotinib in patient with ALK positive non small cell lung cancer (NSCLC): Real-world findings5

1Vázquez-Estévez, S; et al. Journal of Clinical Oncology 2012 30:15_suppl, e18146;2Fírvida-Pérez, JL; et al. Journal of Clinical Oncology 2012 30:15_suppl, e18040;3Agraso-Busto, S; et al. Journal of Clinical Oncology 2019 37:15_suppl, e20654;4Agraso-Busto, S; et al. Journal of Clinical Oncology 2019 37:15_suppl, e20662;

5Azpitarte-Raposeiras, C; et al. Journal of Clinical Oncology 2019 37:15_suppl, e20636

ANO TÍTULO DA PUBLICACIÓN

2016 An observational study of the efficacy and safety of nivolumab in pretreated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group Clinical Practice1

2017 The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice2

2019Utility of the Lung Inmune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab3

1Areses-Manrique, C; et al. Journal of Clinical Oncology 2016 34:15_suppl, e20612; 2Areses, MC, et al. Journal of Clinical Oncology 2017 35:15_suppl, e20564;

3Ruiz-Bañobre, J; et al. Journal of Clinical Oncology 2019 37:15_suppl, e20645

ANO TÍTULO DA PUBLICACIÓN

2013 Concurrent chemoradiation (CChRT) with bi-weekly docetaxel and cisplatin and thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A phase II study from the Galician Lung Cancer Group1

2017 Concurrent Chemoradiation (CChRT) for locally advanced stage III Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group2

1Casal-Rubio, J; et al. Journal of Clinical Oncology 2013 31:15_suppl, 7549; 2Gómez-García, S; et al. Journal of Clinical Oncology 2017 35:15_suppl, e20067

ANO TÍTULO DA PUBLICACIÓN

2015 Phase II trial of Carboplatin and Pemetrexed combination in early patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). A Galician Lung Cancer Lung Study1

2019 Third and successive-lines of chemotherapy in NSCLC patientes without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón2

1Areses-Manrique, MC; et al. Journal of Clinical Oncology 2015 33:15_suppl, e190172Afonso-Afonso, FJ; et al. Journal of Clinical Oncology 2019 37:15_suppl, e20579

ANO TÍTULO DA PUBLICACIÓN

2016 ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective study—GGCP 052/12

Pena, C; et al. Journal of Clinical Oncology 2016 34:15_suppl, e20533